What it really means when we say ‘U.S.-compounded’

Most peptide and GLP-1 companies don’t make their own medications. Neither do we.

The difference is where they get them from.

Compounding pharmacies are a category of pharmacy regulated under federal law to produce custom medications under a valid prescription. The 503A designation means a pharmacy is licensed to compound for individual patients — your prescription, your bottle, your lot number on the label.

That’s the model the BioCore team chose. Every medication you receive from us is compounded at a U.S.-based 503A-licensed pharmacy. Domestic. Inspected. Traceable. Operating under both federal and state regulatory frameworks.

It’s also the model many of our competitors don’t follow.

A lot of what’s sold online as ‘research peptides’ comes from international sources — usually Chinese manufacturers with limited regulatory oversight, sold through reseller chains where chain of custody breaks down by the time the product reaches a patient. The same is true for some of the cheaper ‘telehealth’ GLP-1 services: the bulk product comes from offshore.

That’s not what we do.

It’s why we charge $35 flat shipping with cold-chain handling — your medication has to arrive intact and correctly stored. It’s why our medical director writes every prescription and reviews every refill. It’s why your $149 annual telehealth covers labs, dose adjustments, and ongoing oversight rather than acting as a one-time gate to a refill subscription.

Compounded doesn’t mean knockoff. It means custom-prepared by a regulated pharmacy under a valid prescription. The active molecule is the same one in the brand-name versions. The compounding model is what makes it accessible without the brand-name pricing.

If you’re shopping the peptide and GLP-1 market and a price looks too good — it usually is. Ask where the medication is sourced. Ask for a 503A license number. Ask who reviews your labs.

The boring answers are the right ones.

— The BioCore Team